Recent biopharmaceutical initial public offerings show that the IPO boom is not limited to the US, and illustrate the challenges of going public in any market.
US stock values have plummeted in recent weeks, including drug developer stocks, which should make it more difficult for some...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?